ketamine has been researched along with Colorectal Neoplasms in 6 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ninety-two patients undergoing laparoscopic radical resection of colorectal cancer were randomly assigned to either the esketamine (K group) or non-eskatamine (C group) group." | 9.69 | Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. ( Ai, Y; He, L; Liu, S; Xu, Y; Zhang, C, 2023) |
| "This study aimed at examining the effect of a single sub-anesthetic dose of ketamine on postoperative fatigue syndrome (POFS) in patients undergoing radical laparoscopic surgery for colorectal cancer (CRC)." | 9.51 | Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study. ( Cheng, H; Zhang, H; Zhao, L, 2022) |
| "Intraoperative low-dose ketamine administration did not convey any favourable impacts on overall postoperative NK cell activity, inflammatory responses, and prognosis in colorectal cancer surgery patients." | 9.41 | The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. ( Cho, JS; Jun, JH; Kim, NY; Kwak, YL; Lee, S; Shim, JK, 2021) |
| " Ninety-two patients undergoing laparoscopic radical resection of colorectal cancer were randomly assigned to either the esketamine (K group) or non-eskatamine (C group) group." | 5.69 | Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. ( Ai, Y; He, L; Liu, S; Xu, Y; Zhang, C, 2023) |
| "Ketamine treatment inhibited colon cancer cell viability and migration in HT29 and SW480 cells." | 5.56 | Ketamine inhibits aerobic glycolysis in colorectal cancer cells by blocking the NMDA receptor-CaMK II-c-Myc pathway. ( Duan, W; Hu, J; Liu, Y, 2020) |
| "This study aimed at examining the effect of a single sub-anesthetic dose of ketamine on postoperative fatigue syndrome (POFS) in patients undergoing radical laparoscopic surgery for colorectal cancer (CRC)." | 5.51 | Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study. ( Cheng, H; Zhang, H; Zhao, L, 2022) |
| "Intraoperative low-dose ketamine administration did not convey any favourable impacts on overall postoperative NK cell activity, inflammatory responses, and prognosis in colorectal cancer surgery patients." | 5.41 | The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. ( Cho, JS; Jun, JH; Kim, NY; Kwak, YL; Lee, S; Shim, JK, 2021) |
| "Ketamine treatment inhibited colon cancer cell viability and migration in HT29 and SW480 cells." | 1.56 | Ketamine inhibits aerobic glycolysis in colorectal cancer cells by blocking the NMDA receptor-CaMK II-c-Myc pathway. ( Duan, W; Hu, J; Liu, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, L | 1 |
| Zhang, H | 1 |
| Cheng, H | 1 |
| Xu, Y | 1 |
| He, L | 1 |
| Liu, S | 1 |
| Zhang, C | 1 |
| Ai, Y | 1 |
| Hu, J | 2 |
| Duan, W | 2 |
| Liu, Y | 2 |
| Cho, JS | 1 |
| Kim, NY | 1 |
| Shim, JK | 1 |
| Jun, JH | 1 |
| Lee, S | 1 |
| Kwak, YL | 1 |
| Blaj, C | 1 |
| Bringmann, A | 1 |
| Schmidt, EM | 1 |
| Urbischek, M | 1 |
| Lamprecht, S | 1 |
| Fröhlich, T | 1 |
| Arnold, GJ | 1 |
| Krebs, S | 1 |
| Blum, H | 1 |
| Hermeking, H | 1 |
| Jung, A | 1 |
| Kirchner, T | 1 |
| Horst, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection[NCT03273231] | 100 participants (Anticipated) | Interventional | 2017-09-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for ketamine and Colorectal Neoplasms
| Article | Year |
|---|---|
Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study.
Topics: Anesthetics; Colorectal Neoplasms; Double-Blind Method; Fatigue; Humans; Interleukin-6; Ketamine; La | 2022 |
Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial.
Topics: Colorectal Neoplasms; Double-Blind Method; Humans; Ketamine; Laparoscopy; Pain, Postoperative; Prosp | 2023 |
The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial.
Topics: Colorectal Neoplasms; Double-Blind Method; Humans; Immunomodulation; Interleukin-6; Ketamine; Tumor | 2021 |
3 other studies available for ketamine and Colorectal Neoplasms
| Article | Year |
|---|---|
Ketamine inhibits aerobic glycolysis in colorectal cancer cells by blocking the NMDA receptor-CaMK II-c-Myc pathway.
Topics: Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Movement; C | 2020 |
Ketamine inhibits colorectal cancer cells malignant potential via blockage of NMDA receptor.
Topics: Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Excitatory Amino Acid Antagonists; Humans; Ke | 2019 |
ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer.
Topics: Animals; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Gene Expression Regula | 2017 |